(HealthDay)—Real-world evidence shows that rivaroxaban reduces the risk for recurrent venous thromboembolism (VTE) in morbidly obese patients, with similar safety and efficacy as warfarin, according to a study published in the October issue of Thrombosis Research. Alex C. Spyropoulos, M.D., from Northwell Health System in New York City, and colleagues used two U.S. claims databases...